Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
First-line Treatment with RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 110
- Registration Number
- NCT06730373
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳Shengli Oilfield Central Hospital, Dongying, Shandong, China
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 726
- Registration Number
- NCT06731478
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 81
- Registration Number
- NCT06686394
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT06650332
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)
- Conditions
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 153
- Registration Number
- NCT06625775
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Suzhou Teligene Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06589830
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 550
- Registration Number
- NCT06532006
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 143
- Registration Number
- NCT06510465
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳Renji Hospital, Shanghai, China
The Sagittarius Trial
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-11-11
- Target Recruit Count
- 700
- Registration Number
- NCT06490536
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇹Istituto di Candiolo, Candiolo, Torino, Italy
🇮🇹Azienda Sanitaria Locale di Biella, Biella, Italy
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 28
- Registration Number
- NCT06441890
- Locations
- 🇺🇸
University of Illinois, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.